We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$701M
AUM Growth
+$112M
Cap. Flow
+$22.9M
Cap. Flow %
3.26%
Top 10 Hldgs %
45.26%
Holding
159
New
30
Increased
40
Reduced
26
Closed
28

Top Buys

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14.1M
2
AGN
Allergan plc
AGN
+$14M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$9M
4
MRK icon
Merck
MRK
+$6.67M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.17M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.99M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 65.28%
2 Miscellaneous 21.58%
3 Technology 5.67%
4 Communication Services 4.68%
5 Industrials 1.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.7B
$121M 17.29%
+1,400,000
New +$112M
CELG
2
DELISTED
Celgene Corp
CELG
$40.1M 5.72%
275,000
+25,000
+10% +$3.41M
BIIB icon
3
Biogen
BIIB
$32.4B
$32.9M 4.69%
105,000
+15,000
+17% +$4.44M
MRK icon
4
Merck
MRK
$363B
$27.2M 3.88%
445,400
+110,040
+33% +$6.67M
GILD icon
5
Gilead Sciences
GILD
$187B
$18.6M 2.66%
230,000
– –
GSK icon
6
GSK
GSK
$102B
$18.3M 2.61%
360,000
– –
SRPT icon
7
Sarepta Therapeutics
SRPT
$2.18B
$17.5M 2.49%
384,997
+1,950
+0.5% +$77.9K
CEL
8
DELISTED
Cellcom Israel, Ltd.
CEL
$14.3M 2.04%
+1,535,988
New +$14.1M
PFE icon
9
Pfizer
PFE
$157B
$13.9M 1.99%
411,060
– –
SHPG
10
DELISTED
Shire pic
SHPG
$13.2M 1.89%
86,500
+18,000
+26% +$2.82M
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$13M 1.86%
158,000
+65,000
+70% +$5.15M
AGN
12
DELISTED
Allergan plc
AGN
$12.3M 1.75%
+60,000
New +$14M
TSRO
13
DELISTED
TESARO, Inc.
TSRO
$10.3M 1.47%
80,000
+25,000
+45% +$3.1M
CLLS
14
Cellectis
CLLS
$148M
$9.92M 1.42%
348,736
+144,972
+71% +$3.75M
NICE icon
15
Nice
NICE
$6.17B
$8.88M 1.27%
109,159
+24,107
+28% +$1.87M
ITRN icon
16
Ituran Location and Control
ITRN
$1.04B
$8.27M 1.18%
229,283
-75,138
-25% -$2.45M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$12.6B
$7.91M 1.13%
85,000
+10,000
+13% +$884K
PTLA
18
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$7.83M 1.12%
145,000
+105,000
+263% +$6.16M
ALDX icon
19
Aldeyra Therapeutics
ALDX
$84.5M
$7.52M 1.07%
1,044,131
+168,200
+19% +$878K
ORBK
20
DELISTED
Orbotech Ltd
ORBK
$7.4M 1.06%
175,243
-38,497
-18% -$1.47M
TEVA icon
21
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$7.04M 1%
+400,000
New +$9M
KYNB
22
Kyntra Bio
KYNB
$29.8M
$6.98M 1%
5,191
-1,437
-22% -$1.51M
SRPT icon
23
CALL
Sarepta Therapeutics
SRPT
$2.18B
$6.8M 0.97%
+150,000
New +$5.99M
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.38M 0.91%
+205,000
New +$6.17M
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$6.33M 0.9%
420,000
+20,000
+5% +$265K
1
2 3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sphera Funds Management held 159 positions worth $701M, up 19% from $589M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $22.9M of net new capital in Q3 2017, opening 30 new positions and adding to 40 existing holdings. Its largest new stake was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 68% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Caesarstone, an estimated $3.28M trimmed.

  • Sphera Funds Management's largest Q3 2017 buy was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.
  • Sphera Funds Management added most to Merck in Q3 2017, an estimated $6.67M increase.
  • Sphera Funds Management's biggest Q3 2017 reduction was Caesarstone, cutting an estimated $3.28M.
  • Sphera Funds Management fully exited Novartis in Q3 2017, selling an estimated $16M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $701M portfolio in Q3 2017.
  • Sphera Funds Management opened 30 new positions and closed 28 in Q3 2017.
  • Sphera Funds Management's portfolio value rose 19% quarter-over-quarter to $701M.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.